🔎 Trials Near Me

Beranda › Limfoma Folikuler › Washington › Seattle

Uji klinis Limfoma Folikuler di Seattle, WA

15 studi untuk Limfoma Folikuler mencari peserta di lokasi sekitar Seattle (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Menerima pesertaFase 1/2
  • Research Site, Seattle
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06542250

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Menerima pesertaFase 1/2
  • Fred Hutchinson Cancer Research Center, Seattle
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05006716

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Menerima pesertaFase 1
  • University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07226843

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Menerima pesertaFase 1
  • Swedish Cancer Institute (SCI), Seattle
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07101328

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Menerima pesertaFase 3
  • Fred Hutch Cancer Center, Seattle
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT05303519

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Menerima pesertaFase 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT06442475

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Menerima pesertaFase 1
  • Fred Hutchinson Cancer Center, Seattle
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT07121946

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Menerima pesertaFase 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Jun 2026 · NCT06948786

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Menerima pesertaFase 2Sukarelawan sehat diterima
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
6 Months · Semua jenis kelamin · Diperbarui 29 Mei 2026 · NCT04195633

Study of SGR-1505 in Mature B-Cell Neoplasms

Menerima pesertaFase 1
  • Fred Hutchinson Cancer Center, Seattle
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT05544019

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Menerima pesertaFase 1/2
  • University of Washington-Seattle Cancer Care Alliance, Seattle
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jan 2026 · NCT04669171

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Menerima pesertaStudi observasional
  • Massive Bio SYNERGY-AI site, Seattle
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Menerima pesertaFase 1
  • Swedish Cancer Institute, Seattle
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2025 · NCT05780034

Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients

Menerima peserta
  • University of Washington Medical Center, Seattle
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Feb 2021 · NCT02537769

Uji klinis Limfoma Folikuler di kota lain

Studi lain di Seattle

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.